Quantum Genomics Logo

Quantum Genomics

Biopharma developing cardiovascular treatments, now in judicial liquidation.

ALQGC | PA

Overview

Corporate Details

ISIN(s):
FR0010783837 (+4 more)
LEI:
969500TFCD8K9RPM9K97
Country:
France
Address:
6 RUE CAMBACERES, 75008 PARIS
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Quantum Genomics is a biopharmaceutical company focused on developing treatments for unmet medical needs, particularly in cardiovascular diseases such as hypertension and heart failure. The company's research was centered on a novel therapeutic approach involving Brain Aminopeptidase A Inhibition (BAPAI), with its lead drug candidate being firibastat. In early 2024, Quantum Genomics acquired the company Exactcure. However, recent developments indicate that the company has subsequently filed for judicial liquidation.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-06-13 18:00
Post-Annual General Meeting Information
Report de l'Assemblée Générale Mixte du 30/06/2025
French 116.4 KB
2025-04-30 20:00
Earnings Release
Quantum Genomics publishes its 2024 annual financial statements and announces a…
English 206.5 KB
2025-04-30 20:00
Delisting Announcement
Quantum Genomics publie ses comptes annuels 2024 et annonce un changement de li…
French 254.0 KB
2025-04-08 08:00
Delisting Announcement
Quantum Genomics fait un point sur sa situation
French 688.8 KB
2025-04-08 08:00
Delisting Announcement
Quantum Genomics provides an update on its situation
English 626.0 KB
2024-10-29 18:00
Earnings Release
Quantum Genomics publie ses résultats du 1er semestre 2024 et annonce la nomina…
French 241.2 KB
2024-09-27 08:00
Legal Proceedings Report
Quantum Genomics sécurise un financement avec le fonds Akkadian Partners Fund e…
French 74.5 KB
2024-09-04 18:00
Legal Proceedings Report
Quantum Genomics reviewed its financial situation and announced that it has fil…
English 175.5 KB
2024-09-04 18:00
Legal Proceedings Report
Quantum Genomics fait un point sur sa situation financière et annonce qu'elle a…
French 150.0 KB
2024-07-03 13:00
Capital/Financing Update
BILAN SEMESTRIEL S1 DU CONTRAT DE LIQUIDITE CONTRACTE AVEC LA SOCIETE DE BOURSE…
French 275.3 KB
2024-03-13 18:00
Business and Financial Review
Quantum Genomics publie ses résultats de l'exercice 2023. Le rapprochement avec…
French 193.8 KB
2024-03-13 18:00
Earnings Release
Quantum Genomics publishes its results for the 2023 financial year. The merger …
English 166.3 KB
2024-01-10 16:35
Capital/Financing Update
Bilan au 29 décembre 2023 du contrat de liquidité contracté avec la Société de …
English 297.2 KB
2024-01-10 16:30
Capital/Financing Update
Bilan au 29 décembre 2023 du contrat de liquidité contracté avec la Société de …
English 297.2 KB
2023-12-14 18:05
Regulatory News Service
Quantum Genomics enters into exclusive negotiations with ExactCure
English 286.1 KB

Automate Your Workflow. Get a real-time feed of all Quantum Genomics filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Quantum Genomics via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Kamada Ltd. Logo
Develops specialty plasma-derived therapeutics for rare and serious conditions.
Israel KMDA
KANABO GROUP PLC Logo
Develops cannabis formulas and vaporization devices for the medical and consumer wellness markets.
United Kingdom KNB
Kancera Logo
Develops small molecule drugs targeting the fractalkine axis for cancer and inflammatory diseases.
Sweden KAN
KANGSTEM BIOTECH CO., LTD. Logo
Develops stem cell therapies for rare diseases; offers culture media, cell platforms, and CDMO services.
South Korea 217730
Karo Pharma AB Logo
Develops and sells everyday healthcare products, focusing on OTC and skin health in Europe.
Sweden KARO
KBIO COMPANY Inc. Logo
Using a plant-based platform to rapidly develop biologics for public health.
South Korea 038530
Keeps Biopharma Inc. Logo
Develops cancer therapies and obesity drugs; manufactures industrial and cleanroom products.
South Korea 256940
Kidswell Bio Corporation Logo
Biopharma R&D of biosimilars, biologics, and cell therapies, with a pediatric focus.
Japan 4584
Kinarus Therapeutics Holding AG Logo
A specialty pharma firm developing and selling medicines for rare and specialty diseases.
Switzerland KNRS
KISSEI PHARMACEUTICAL CO.,LTD. Logo
Develops innovative drugs for urology, renal diseases, and rare or intractable diseases.
Japan 4547

Talk to a Data Expert

Have a question? We'll get back to you promptly.